BIOLASE, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Debt - Additional Information (Detail)

Debt - Additional Information (Detail)							1 Months Ended				9 Months Ended	12 Months Ended
Debt - Additional Information (Detail)	Nov. 18, 2021 USD ($)	Aug. 12, 2020 USD ($)	May 22, 2020 USD ($)	May 07, 2019 USD ($)	May 07, 2019 USD ($)	Nov. 09, 2018 USD ($) d $ / shares shares	Apr. 30, 2021	Mar. 31, 2020 USD ($) $ / shares shares	Nov. 30, 2019 $ / shares	Oct. 31, 2019 $ / shares	Sep. 30, 2021 USD ($)	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2019	Dec. 31, 2018 USD ($)	Feb. 15, 2024 USD ($)	Nov. 15, 2023 USD ($)	Jun. 30, 2022 USD ($)	Feb. 24, 2021 USD ($)	Feb. 10, 2021 $ / shares	May 15, 2020 USD ($)	Sep. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)
Debt Instrument [Line Items]
Change in fair value of warrants												$ (494,000)	$ 0	$ 0
Non current term loans												14,047,000	13,791,000
Debt issuance costs												$ 0	0	25,000
Loan Exit Fees Percentage																	8.00%
Weighted-average interest rate												14.30%
Debt Instrument Maturity Fees				$ 200,000	$ 200,000														$ 100,000
EBITDA target												$ (17,937,000)	(25,338,000)	(16,431,000)
Share price \| $ / shares																						$ 2,575
SWK Warrants
Debt Instrument [Line Items]
Warrants expiration period						8 years
Warrants fair value assumptions, expected volatility rate						81.79%
Warrants fair value assumptions annual dividend per share \| $ / shares						$ 0
Warrants fair value assumptions, risk-free interest rate						3.13%
Change in fair value of warrants						$ 400,000
Number of Warrants Issued \| shares						372,023		487,198
Warrants expire date						Nov. 09, 2026
Initial exercise price of warrants \| $ / shares						$ 3,350		$ 975
Warrants adjusted strike price \| $ / shares								$ 1,225	$ 2,500	$ 1
Number of trading days of average closing price of common stock \| d						10
Additional Warrants issued to purchase shares of common stock \| shares								63,779
Credit Agreement First Amendment
Debt Instrument [Line Items]
Additional warrants to purchase common stock value					100,000
Additional finders fee					100,000
Credit Agreement First Amendment \| SWK Warrants
Debt Instrument [Line Items]
Additional warrants to purchase common stock value					200,000
Business Financing Agreement
Debt Instrument [Line Items]
Note interest rate per annum			3.75%
Non current term loans												$ 150,000	150,000
Loan principal amount			$ 150,000
Loan periodic payment terms			installment payments, including principal and interest, are due monthly beginning in July 2021 and are payable through July 2050. In April 2021, the SBA announced that it was extending the first payment due date for all loans until 2022, or 24 months from the loan execution date. In March 2022, the SBA announced that it was extending the first payment due date for all loans an additional six months, or 30 months from the loan execution date. The Company began making payments on this EIDL Loan starting in November 2022. Fixed payments are first applied to any accrued interest.
Extension of loan due date							2022
Loan balance payment terms			payable through July 2050
Credit Agreement Ninth Amendment [Member]
Debt Instrument [Line Items]
Loan principal amount																				$ 1,000,000
Maximum \| SWK Warrants
Debt Instrument [Line Items]
Change in fair value of warrants								$ 100,000
Initial exercise price of warrants \| $ / shares												$ 2,200
Minimum \| SWK Warrants
Debt Instrument [Line Items]
Initial exercise price of warrants \| $ / shares												$ 3,350
Western Alliance \| Business Financing Agreement
Debt Instrument [Line Items]
Repayments of lines of credit						$ 900,000
SWK Loan
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity																									$ 12,500,000
Interest rate						10.00%
Non current term loans												$ 14,560,000	14,650,000
Line of credit facility term						5 years
Borrowings under lines of credit												$ 13,100
Repayments of lines of credit						$ 700,000
Debt instrument covenant description												(i) maintain unencumbered liquid assets of (A) no less than $1.5 million or (B) the sum of aggregate cash flow from operations less capital expenditures, (ii) achieve certain revenue and EBITDA levels during the first two years of the loan, (iii) limit future borrowing, investments and dividends, and (iv) submit monthly and quarterly financial reporting.
Debt issuance costs																	$ 1,000,000
Interest expense												$ 1,800,000	$ 2,800,000	$ 1,700,000
SWK Loan \| Subsequent Event [Member]
Debt Instrument [Line Items]
Principal Amount Payment																		$ 165,000,000
SWK Loan \| Credit Agreement First Amendment
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				15,000,000	15,000,000
Debt instrument covenant description																(i) adjust minimum revenue and EBITDA levels, (ii) require the Company to have a shelf registration statement declared effective by the Securities and Exchange Commission before September 30, 2019, with a proposed maximum aggregate offering price of at least $10.0 million if the Company does not reach set minimum revenue levels for the three-month period ended September 30, 2019, and (iii) require minimum liquidity of $1.5 million at all times. The First Amendment provided that if aggregate minimum revenue and EBITDA levels were not achieved by September 30, 2019, the minimum liquidity requirement would be increased to $3.0 million, until the Company has obtained additional equity or debt funding of no less than $5.0 million.
Minimum level of liquidity financial covenant				1,500,000	1,500,000
Additional equity or debt funding requirement until minimum liquidity is met				5,000,000	5,000,000
Maximum aggregate offering price				10,000,000
Increase in minimum liquidity requirement if aggregate minimum revenue and EBITDA levels are not achieved				3,000,000	3,000,000
Financial covenant additional borrowings				2,500,000	2,500,000
Loan origination and other fees to be paid				$ 100,000	$ 100,000
SWK Loan \| Credit Agreement, Second Amendment [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity																								$ 5,000,000
Gross proceeds from subordinated debt threshold limit											$ 5,000,000
SWK Loan \| Credit Agreement, Sixth Amendment
Debt Instrument [Line Items]
Repayments of lines of credit		$ 700,000
SWK Loan \| Credit Agreement Eighth Amendment
Debt Instrument [Line Items]
Note maturity date	May 31, 2025
Debt Instrument, Interest Rate, Basis Point	200 basis points
SWK Loan \| Eleventh Amendment to the Credit Agreement [Member]
Debt Instrument [Line Items]
Principal Amount Payment																			$ 700,000,000
SWK Loan \| Maximum
Debt Instrument [Line Items]
Debt instrument covenants unencumbered liquid assets												$ 1,500,000
SWK Loan \| Maximum \| Credit Agreement, Fifth Amendment
Debt Instrument [Line Items]
Subordinated debt issued															$ 10,000,000
SWK Loan \| Maximum \| Credit Agreement, Seventh Amendment
Debt Instrument [Line Items]
Debt instrument covenants unencumbered liquid assets																					$ 15,000,000
SWK Loan \| Maximum \| Credit Agreement Eighth Amendment
Debt Instrument [Line Items]
Debt instrument covenants unencumbered liquid assets	$ 7,500,000
SWK Loan \| Minimum \| Credit Agreement, Fifth Amendment
Debt Instrument [Line Items]
Debt instrument covenants unencumbered liquid assets															3,000,000								$ 1,500,000
Revenue target															41,000,000
EBITDA target															$ 7,000,000
SWK Loan \| Minimum \| Credit Agreement, Seventh Amendment
Debt Instrument [Line Items]
Debt instrument covenants unencumbered liquid assets																					$ 15,000,000